| Literature DB >> 29026211 |
Ferran Sanz1, François Pognan2, Thomas Steger-Hartmann3, Carlos Díaz4, Montserrat Cases4, Manuel Pastor1, Philippe Marc2, Joerg Wichard3, Katharine Briggs5, David K Watson5, Thomas Kleinöder6, Chihae Yang6, Alexander Amberg7, Maria Beaumont8, Anthony J Brookes9, Søren Brunak10, Mark T D Cronin11, Gerhard F Ecker12, Sylvia Escher13, Nigel Greene14, Antonio Guzmán15, Anne Hersey16, Pascale Jacques17, Lieve Lammens18, Jordi Mestres19, Wolfgang Muster20, Helle Northeved21, Marc Pinches22, Javier Saiz23, Nicolas Sajot24, Alfonso Valencia25, Johan van der Lei26, Nico P E Vermeulen27, Esther Vock28, Gerhard Wolber29, Ismael Zamora30.
Abstract
The sharing of legacy preclinical safety data among pharmaceutical companies and its integration with other information sources offers unprecedented opportunities to improve the early assessment of drug safety. Here, we discuss the experience of the eTOX project, which was established through the Innovative Medicines Initiative to explore this possibility.Mesh:
Year: 2017 PMID: 29026211 DOI: 10.1038/nrd.2017.177
Source DB: PubMed Journal: Nat Rev Drug Discov ISSN: 1474-1776 Impact factor: 84.694